This trial is testing a new drug, CG-806, to see if it is safe and effective in treating patients with leukemia or MDS who have relapsed or are unresponsive to other treatments.
- Acute Myeloid Leukemia
- Myelodysplastic Syndrome
3 Primary · 14 Secondary · Reporting Duration: At the end of Cycle 1 (each cycle is 28 days)
Awards & Highlights
1 Treatment Group
Dose Escalation and Expansion
1 of 1
80 Total Participants · 1 Treatment Group
Primary Treatment: CG-806 · No Placebo Group · Phase 1
Who is running the clinical trial?
Age 18+ · All Participants · 3 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
What is the capacity of participants for this research endeavor?
"Aptose Biosciences Inc. needs 80 participants who fulfill the study's prerequisites to successfully complete it. These trials will be conducted at Ochsner Healthcare in Louisiana and Memorial Sloan Kettering Cancer Center in New York City." - Anonymous Online Contributor
What is the principal purpose of this clinical experiment?
"This 28-day trial seeks to ascertain the optimal dosage of CG-806. Further, secondary objectives include measuring pharmacokinetic metrics such as Cmax (maximum plasma concentration), serum half-life, and Cmin (minimum plasma concentration) at designated time points." - Anonymous Online Contributor
Has the FDA approved CG-806 for medical usage?
"CG-806's safety was given a rating of 1 due to the limited information available in its Phase 1 clinical trial, where data on efficacy and security is still being collected." - Anonymous Online Contributor
In what geographical areas are the operations of this trial concentrated?
"Ochsner Healthcare in New Orleans, Memorial Sloan Kettering Cancer Center in NYC, and City of Hope National Medical Center in Duarte are only a few of the medical centres that will be recruiting patients for this trial. There are 9 additional sites where potential participants can apply." - Anonymous Online Contributor
Is the enrollment process currently open for this investigation?
"As per data on clinicaltrials.gov, this medical trial is still open for recruitment. It was first posted on October 6th 2020 and the latest edit to the page occurred on March 4th 2022." - Anonymous Online Contributor